23andMe
phase a study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
45 of 57
Similar slides by 23andMe
See diffirences between slides (animation)
Investor Presentation
August 2022
phase study of me in patients with locally advanced or metastatic solid malignancies study design objectives | 23andMe
Investor Presentation
February 2022
phase study of me in patients with locally advanced or metastatic solid malignancies design objectives | 23andMe
Investor Day
January 2022
phase study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
Related slides by other companies
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Exscientia
Results
March 2024
elucidate phase ongoing in advanced solid | Exscientia
Nuvalent
Investor Presentation
February 2024
the path to patient impact program status first approved a toe pivotal data naive and study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in for her | Nuvalent
Nuvalent
Investor Presentation
January 2024
the path to patient impact ams execute on global registrational strategies pivotal data program status study for phase ongoing with registrational intent for patients with and study for alk demonstrated clinical proof of concept in phase with planned development in both and alk for her planned phase initiation in additional discovery research programs ongoing first approved product mission bringing new best in class medicines to patients with cancer i | Nuvalent
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights